Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BCAX
stocks logo

BCAX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast BCAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCAX is 32.40 USD with a low forecast of 11.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast BCAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCAX is 32.40 USD with a low forecast of 11.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 18.760
sliders
Low
11.00
Averages
32.40
High
48.00
Current: 18.760
sliders
Low
11.00
Averages
32.40
High
48.00
JonesResearch
NULL -> Buy
initiated
$22
2025-09-09
Reason
JonesResearch
Price Target
$22
2025-09-09
initiated
NULL -> Buy
Reason
JonesResearch initiated coverage of Bicara Therapeutics (BCAX) with a Buy rating and $22 price target. The firm says clinical data from Keytruda combinations with bispecific antibodies of Bicara and Merus (MRUS) showed more than doubling of clinical benefits in head and neck cancer. Bicara's "differentiated drug profile offers a compelling investment case," the analyst tells investors in a research note. JonesResearch views the shares as oversold at current levels.
H.C. Wainwright
Robert Burns
Buy
downgrade
$41 -> $40
2025-08-22
Reason
H.C. Wainwright
Robert Burns
Price Target
$41 -> $40
2025-08-22
downgrade
Buy
Reason
H.C. Wainwright analyst Robert Burns lowered the firm's price target on Bicara Therapeutics to $40 from $41 and keeps a Buy rating on the shares following the Q2 report. The firm is factoring in higher long-term operating expenses.
Piper Sandler
Kelsey Goodwin
Overweight
initiated
$36
2025-08-19
Reason
Piper Sandler
Kelsey Goodwin
Price Target
$36
2025-08-19
initiated
Overweight
Reason
Piper Sandler analyst Kelsey Goodwin initiated coverage of Bicara Therapeutics with an Overweight rating and $36 price target. The firm's channel checks highlighted a favorable view on Bicara's patient selection strategy for the pivotal FORTIFi-HN01, ficera's potentially differentiated mDOR, the importance of continued follow-up in relapsed metastatic head and neck squamous cell cancer, and the overall perception that the large market will likely be split longer term, the analyst tells investors in a research note. Piper sees the recent pullback as offering a highly attractive entry point.
Piper Sandler
Kelsey Goodwin
initiated
$36
2025-08-18
Reason
Piper Sandler
Kelsey Goodwin
Price Target
$36
2025-08-18
initiated
Reason
Piper Sandler analyst Kelsey Goodwin initiated coverage of Bicara Therapeutics with an Overweight rating and $36 price target.
Wells Fargo
Eva Fortea Verdejo
Underweight -> Equal Weight
upgrade
$8
2025-05-23
Reason
Wells Fargo
Eva Fortea Verdejo
Price Target
$8
2025-05-23
upgrade
Underweight -> Equal Weight
Reason
Wells Fargo analyst Eva Fortea Verdejo upgraded Bicara Therapeutics to Equal Weight from Underweight with an unchanged price target of $8.
Wells Fargo
Underweight -> Equal Weight
upgrade
$8
2025-05-23
Reason
Wells Fargo
Price Target
$8
2025-05-23
upgrade
Underweight -> Equal Weight
Reason
Wells Fargo upgraded Bicara Therapeutics to Equal Weight from Underweight with an unchanged price target of $8. The form says its Underweight thesis has largely played out on ficerafusp and petosemtamab's head and neck squamous cell carcinomas update. A lower probability of sucess for ficerafusp is largely priced in at current share levels, with a lack of catalysts for upside keeping Bicara range bound in the medium term, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Bicara Therapeutics Inc (BCAX.O) is -6.50, compared to its 5-year average forward P/E of -7.58. For a more detailed relative valuation and DCF analysis to assess Bicara Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.58
Current PE
-6.50
Overvalued PE
-3.94
Undervalued PE
-11.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.15
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.61
Undervalued EV/EBITDA
-6.92

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

BCAX News & Events

Events Timeline

(ET)
2025-11-10
07:31:54
Bicara Therapeutics Announces Q3 Earnings Per Share of 67 Cents, Exceeding Consensus Estimate of 53 Cents
select
2025-10-20 (ET)
2025-10-20
12:44:59
Bicara's Stock Declines Following J&J's Head and Neck Cancer Data Release
select
2025-10-13 (ET)
2025-10-13
07:37:36
Bicara Therapeutics Reveals U.S. FDA Grants Breakthrough Therapy Designation to Ficerafusp Alfa
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-01Newsfilter
Bicara Reports Ficerafusp Alfa Clinical Data, 57% Response Rate at 750mg Dose
  • Clinical Trial Progress: Bicara Therapeutics reports a 57% objective response rate for 750mg of ficerafusp alfa combined with pembrolizumab in the Phase 1b expansion cohort for 1L HPV-negative recurrent/metastatic head and neck squamous cell carcinoma, indicating significant therapeutic potential.
  • Safety Analysis: The safety profile of this combination aligns with known characteristics of ficerafusp alfa and pembrolizumab, enhancing confidence in its clinical application and potentially accelerating FDA approval processes.
  • Conference Presentation: Bicara will present these preliminary data at the European Society for Medical Oncology Congress on December 6, 2025, further elevating the company's visibility and influence in the biopharmaceutical sector.
  • Market Demand: Given the treatment needs of head and neck squamous cell carcinoma patients, the development of ficerafusp alfa not only addresses a critical market gap but also has the potential to improve patient quality of life, meeting the growing demand for effective therapies.
[object Object]
Preview
9.0
11-20Globenewswire
Reassessing Biotech Pipelines: The Valuation Indicator Investors Have Anticipated

  • Fair-Value Remeasurement Importance: Fair-value remeasurements under U.S. GAAP are becoming essential for late-stage biotech companies, providing insights into the financial implications of scientific advancements and enhancing shareholder value.

  • Oncotelic's Valuation Milestone: Oncotelic Therapeutics is set to undergo a significant fair-value remeasurement of its 45% stake in GMP Bio, with a new valuation indicating a potential asset value of approximately $765 million, reflecting progress in its oncology-focused pipeline.

  • Advancements in Clinical Programs: Oncotelic's pipeline includes multiple late-stage oncology and rare disease programs, with significant milestones achieved, such as advancements in OT-101 for pancreatic cancer and other promising candidates targeting various conditions.

  • Nanomedicine Market Growth: The valuation of Oncotelic's Deciparticle nanomedicine platform is tied to the growing market for nanomedicine, projected to exceed $350 billion by 2032, highlighting the potential for substantial financial recognition as clinical developments progress.

[object Object]
Preview
4.0
11-11Benzinga
Wells Fargo Keeps Equal-Weight Rating on Bicara Therapeutics and Increases Price Target to $11
  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time market intelligence to help them make informed decisions.
  • Exclusive Content: The platform features exclusive stories and insights generated by Benzinga reporters, catering to serious traders looking for an edge in the market.
  • Community Engagement: Over 10,000 traders are part of the Benzinga Pro community, emphasizing the platform's popularity and reliability among serious market participants.
  • Market Winning Strategy: The service is designed to help traders win in the markets every day by delivering timely and accurate stock market information.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Bicara Therapeutics Inc (BCAX) stock price today?

The current price of BCAX is 18.76 USD — it has increased 3.3 % in the last trading day.

arrow icon

What is Bicara Therapeutics Inc (BCAX)'s business?

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.

arrow icon

What is the price predicton of BCAX Stock?

Wall Street analysts forecast BCAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCAX is 32.40 USD with a low forecast of 11.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Bicara Therapeutics Inc (BCAX)'s revenue for the last quarter?

Bicara Therapeutics Inc revenue for the last quarter amounts to -40.68M USD, increased 97.19 % YoY.

arrow icon

What is Bicara Therapeutics Inc (BCAX)'s earnings per share (EPS) for the last quarter?

Bicara Therapeutics Inc. EPS for the last quarter amounts to -29290000.00 USD, increased 69.97 % YoY.

arrow icon

What changes have occurred in the market's expectations for Bicara Therapeutics Inc (BCAX)'s fundamentals?

The market is revising No Change the revenue expectations for Bicara Therapeutics Inc. (BCAX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 55.56%.
arrow icon

How many employees does Bicara Therapeutics Inc (BCAX). have?

Bicara Therapeutics Inc (BCAX) has 55 emplpoyees as of December 05 2025.

arrow icon

What is Bicara Therapeutics Inc (BCAX) market cap?

Today BCAX has the market capitalization of 1.03B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free